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Abstract
Clostridium difficile (C. difficile) is a gram-positive bacterium that comprises part
of the healthy human gut microbiome. When it gains sufficient access to peptides, C.
difficile flourishes and releases tissue-damaging toxins, which cause inflammation of the
colon that can develop into a Clostridium difficile Infection (CDI).10 The Ivey Laboratory
believes that the best tactic in preventing CDIs is stopping peptide ingestion, which
theoretically could be accomplished by manipulating the oligopeptide permease (App)
system.7 In order to verify that altering the App system would successfully impede
peptide uptake, first the expression of the app Promoter Region (appProR) of C.
difficile’s DNA needs to be better understood. This characterization can be accomplished
by fusing appProR to the gfp-reporter gene, which codes for Green Fluorescent Protein
(GFP). GFP emits green fluorescent light when exposed to blue or ultraviolet light, and
the degree of fluorescence can be used to quantify the gene expression of whatever DNA
sequence to which the gfp-reporter gene is fused.9
The specific aim of this project was to incorporate the appProR-gfp-reporter gene
complex first into Eschericheria coli (E. coli), and then into Bacillus subtilis (B. subtilis).
Those two bacterial species were chosen as hosts for the transformations, for E. coli and
B. subtilis are known for being more receptive to recombinant DNA techniques than C.
difficile.22 By ligating the appProR-gfp-reporter gene sequence of pUA321 to pG+host4,
the resulting plasmid, pUA625, contained a broad enough host range to transform both
gram-negative E. coli and gram-positive B. subtilis. Those successful transformations
indicate that pUA625 could be integrated into C. difficile in the future, an achievement
which would lead to a better understanding of the expression of C. difficile’s App system.

	
  

4	
  

Introduction
Clostridium difficile is a gram-positive, pathogenic obligate anaerobe that resides
in the human gastrointestinal tract. As is typical of many strictly anaerobic bacteria that
inhabit the human gut, C. difficile produces endospores as a means of pathogenesis and,
ultimately, survival.10 While vegetative C. difficile cells are anaerobic, its spores do not
require oxygen-free conditions and can persist in a variety of environments for extended
periods of time.18 Once a potential host consumes C. difficile spores, the spores can
develop into vegetative, toxin-releasing cells. These cytotoxins damage epithelial colon
tissue and cause what has appropriately been termed a Clostridium difficile Infection.10
CDIs often involve pseudomembranous colitis, or inflammation of the large intestine.
Symptoms of CDI-associated pseudomembranous colitis can include abdominal pain and
fever, but its most characteristic presentations are diarrhea (which can range from mild to
extreme) and the accompanying unpleasant odor. The more severe cases can be lethal,
earning CDIs the reputation of being the main cause of gastroenteritis fatalities in the
United States.3 From 2005 to 2009 the CDI prevalence rate doubled to 140 cases per
10,000 hospital discharges, resulting in upwards of 500,000 new instances of CDI in the
U.S. each year.3,4 These alarming statistics demonstrate how critical it is that better CDI
treatment options are developed.
While C. difficile is a standard part of the human gut microbiome, CDIs do not
become an issue until the normal intestinal flora has become disrupted. This disruption
most often occurs through the use of antibiotics, thus explaining why CDIs are almost
exclusively restricted to patients in hospitals who are receiving antibiotic therapy.3
Antimicrobial treatments specifically involving penicillin analogues, fluoroquinolones,
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clindamycin, or cephalosporins are implicated in most CDI incidences.11 These
antibiotics kill a large portion of the bacteria in the gastrointestinal tract, but the spores of
C. difficile are resistant to these antimicrobials.10 When other intestinal bacterial species
have been suppressed, C. difficile no longer has
to compete for its nutrient of choice, peptides.
The uptake of these peptides is facilitated by
the oligopeptide permease (App) system,
particularly by subunits App A, B, D, and F
(figure 1).7 The App system also plays a role in
the colonization abilities of C. difficile, for App
A gives C. difficile the ability to bind to
Figure 1: Subunits of the App System; image
generated using the Microsoft Paint Application.

intestinal epithelial cells.7

Once well-nourished C. difficile has attached to the luminal side of the epithelial
cells of the colon, it begins releasing cytotoxins A and B. It is hypothesized that the
release of these toxins is prompted by the peptides’ dual function as pheromones. Grampositive bacteria, such as Bacillus subtilis and Staphylococcus aureus, have been known
to utilize peptide pheromone systems as a means of chemical signaling to stimulate
synchronized cellular responses among bacterial communities.6 Though this phenomenon
has not yet been confirmed in C. difficile, the notion that the uptake of peptides
communicates to C. difficile that the weakened gut microbiome is now vulnerable to its
toxins seems a likely possibility.
Following their release from the vegetative C. difficile cells, the cytotoxins bind to
the epithelial intestinal cells’ receptors and enter the cytosol of their new host cells. Next,
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Toxins A and B target the host Rho GTPases, which are proteins that regulate numerous
cellular processes, including transcription, phagocytosis, actin cytoskeleton maintenance,
and other vital activities.5 The cytotoxins alter the Rho GTPases via mono-Oglucolysation, a modification that disrupts the functionality of the Rho GTPases and
eventually leads to cell death by apoptosis (figure 2). This widespread intestinal epithelial
cell death causes inflammation of the colon, which then progresses into a CDI.5

Figure 2: Effects of Glucosylation by Toxin A and B on RhoGTPases.14

Once a patient has been diagnosed with a CDI, the first step of treatment involves
stopping whatever antibiotics the patient is currently consuming. Next, the patient is
typically prescribed a different antibiotic that specifically targets the endospore-forming
capacities of C. difficile, a skill that is crucial for the survival and consequent
pathogenesis of the bacterium. Without its highly resistant spores, C. difficile can no
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longer withstand penicillin or other common antibiotic treatments associated with CDIs;
therefore, C. difficile cannot persist long enough to gain access to peptides and produce
its infection-causing toxins. Historically vancomycin has been thought to be the most
effective antibiotic in battling CDIs, but recent studies have offered a better option:
fidaxomicin. While both drugs rapidly reduce the amount of vegetative cells in CDI
patients, patients receiving vancomycin have a much higher recurrence rate.
Fidaxomicin’s dominance is likely attributed to two factors: it causes a larger decrease in
C. difficile spore counts, and it maintains a greater portion of the healthy gastrointestinal
microbiome. By preserving other bacterial species, C. difficile remains starved for
peptides and is unable to cause an infection. While fidaxomicin may be produce better
results than vancomycin, the 20% relapse rate of patients using fidaxomicin suggest that
there is still plenty of room for CDI treatment improvement.12
Studies suggest that C. difficile is evolving at a rapid rate, become more virulent
and even less responsive to traditional antibiotic treatments. This worrisome observation
highlights the need for a new type of CDI therapy. A promising alternative to drugs is the
fecal microbiota transplant (FMT). As its name suggests, FMT is the transfer of fecal
matter from a healthy individual into the gastrointestinal tract of a CDI patient. The
healthy stool sample contains normal gut flora, and the re-introduction of those bacteria
into the colon of the CDI patient reestablishes bacterial homeostasis and disturbs C.
difficile’s unregulated proliferation. While the gruesome nature of an FMT may not seem
like a desirable option for CDI patients, its impressive cure rate of roughly 94% will
likely increase the frequency of FMTs in the future.18
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Ideally, a technique should be developed that prevents CDIs from occurring and,
thus, renders CDI antibiotic treatments and FMTs unnecessary. The work performed in
the Ivey Laboratory operates under the notion that the best method of stopping CDIs is to
inhibit C. difficile’s peptide intake, which could have a two-fold affect. First, vegetative
C. difficile cell growth should be hindered, for the lack of nutrient consumption should
limit C. difficile’s proliferation capacities. Ceasing peptide ingestion could also obstruct
cytotoxin release, assuming that peptides do indeed act as a communication method in C.
difficile. In theory, this goal of peptide restriction could be accomplished by manipulating
the app promoter region (appProR), which is the sequence of DNA that controls gene
expression of the peptide-consuming App system.7 Before this manipulation can occur,
however, a better understanding of appProR is required. To further characterize this
segment of DNA, the Ivey Laboratory utilizes the green fluorescent protein (GFP). GFP
is a protein comprised of 238 amino acids and is found in the jellyfish species Aequorea
victoria.9,17 When exposed to U.V. or blue light, GFP emits green fluorescence.9 Since its
discovery, this fluorescent aspect of GFP has been used to analyze various cellular
activities, including gene expression.17 By fusing the gfp-reporter gene to the DNA
sequence of choice and cultivating cells containing this gene construct, the degree of
fluorescence in the resulting colonies serves as an indicator of that specific gene’s
expression. Since the Ivey Laboratory aims to characterize the App system of C. difficile,
the gfp-reporter gene has been attached to the appProR sequence in a plasmid called
pUA321. By inserting the DNA sequence coding for the appProR-gfp-reporter gene
complex into C. difficile, the amount of fluorescence in the transformed C. difficile cells
can be quantified as a means of measuring the degree of appProR expression. Further
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characterizing appProR expression should clarify whether or not manipulating the App
system is a viable option for impeding C. difficile growth and pathogenesis.
Unfortunately, transforming C. difficile is no easy task. Before attempting to
insert pUA321 into C. difficile, one must start with a more cooperative bacterial species.
For this experiment, E. coli was chosen as the primary transformation candidate, for it is
celebrated as being one of the most compliant bacterial species when subjected to
recombinant DNA techniques.22 Once the desired DNA sequence has successfully been
inserted into the E. coli DNA, one can then attempt to transform a species that is more
similar to C. difficile, such as B. subtilis. This transition is necessary because gramnegative E. coli (while it can be fairly easily transformed) is not a good model organism
for how a gram-positive species such as C. difficile would react during a transformation.
Therefore, the appProR-gfp-reporter gene complex from E. coli must be transferred to the
more cooperative gram-positive B. subtilis before a C. difficile transformation would be a
feasible endeavor.
The specific goal of this project is to transform B. subtilis, the realization of which
would be indicated by the production of green fluorescent B. subtilis colonies. The
successful recombination of the appProR-gfp-reporter gene construct into B. subtilis
would pave the way for the future incorporation of the DNA sequence into C. difficile,
which would help the Ivey Laboratory further analyze C. difficile’s App system and bring
CDIs one step closer to eradication.
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Materials and Methods
Materials and Definitions:
Material

Definitions

pUA321

Plasmid containing
appProR and gfp
+
pG host4
Broad host range plasmid
containing Ori Ts
pUA625
Plasmid created via the
ligation of pUA321 and
pG+host4
LB Miller Broth
Base for maintenance and
proliferation of E. coli
Brain Heart Infusion (BHI) Base for maintenance and
Broth
proliferation of B. subtilis
Bacto agar
Solidifying agent for LB,
BHI broth media
Erythromycin (Em)
Antibiotic used to select
for transformed cells
containing pUA625 and to
prevent unwanted bacterial
growth
UP101
Universal primer
AppProR
Primer for appProR
Master mix, 2x
Mixture containing Taq
DNA polymerase, dNTPs,
MgCl2, and reaction
buffer; used for PCR
amplification of DNA
templates ranging from
0.2-2 kb
Vent
DNA polymerase;
proofreads and prevents
mutations in DNA of PCR
product
dH2O
Deionized water
TAE, 1x
Buffer utilized in gel
electrophoresis
NEBuffer 2.1
Digest buffer
HindIII
EcoR1
	
  

Restriction enzyme
Restriction enzyme

Source
Ivey Lab
Ivey Lab

IBI Scientific
EMD
SIGMA Chemical
Company
Ivey Lab

Bio-Rad
IDT
Promega

New England BioLabs,
Inc.
Ivey Lab
Ivey Lab
New England BioLabs,
Inc.
Life Technologies
Promega
11	
  

XbaI
T4 Buffer, 10x
T4 Ligase

Life Technologies
New England BioLabs,
Inc.
New England BioLabs,
Inc.
Omega Bio-Tek

MicroElute Cycle Pure Kit

Kit containing materials
and protocol for a
purification

MicroElute DNA Cleanup
Kit

Kit containing materials
and protocol for a DNA
purification

Omega Bio-Tek

DH5α

Electrocompetent
Escherichia coli cells

Invitrogen

BD366

Electrocompetent Bacillus
subtilis cells

Ivey Lab

Glycerol

Base for the stock solution
containing pUA625
Kit containing materials
and protocol for a largescale plasmid preparation

Ivey Lab

Component of ethanol
precipitation
Components of ethanol
precipitation
Agarose specifically
designed for gel
electrophoresis
DNA stain used in gel
electrophoresis; gets
excited by blue light
Creates a ladder from
which the size of the
sample is assessed via gel
electrophoresis
Dyes the sample DNA so
that it can be assessed via
gel electrophoresis

Ivey Lab

Plasmid DNA Maxi Kit

NaCl, 5M
Ethanol, 95%, 70%
SeaKem GTG Agarose
SYBR Safe
1 kb marker

Loading buffer, 2x

	
  

Restriciton enzyme
Buffer for ligation
involving T4 ligase
Ligation enzyme

Omega Bio-Tek

Ivey Lab
FMC BioProducts
Life Technologies
Ivey Lab

Ivey Lab

12	
  

Methods:
Media and Growth Conditions:
LB Miller Broth, Erythromycin Plates:
The medium for the LBEm500 plates was prepared using 200mL H2O, 5g LB
Miller Broth, 3g bacto agar, and 1mL Em100. The transformed E. coli (DH5α) cells were
spread on these plates, which were then placed in a 30°C incubation chamber for 7 days.
LB Miller, Erythromycin Broth Culture:
The broth culture utilized the same medium as the LBEm500 plates described
above. A fluorescent colony from the LBEm500 plates was picked and placed in a test tube
containing LBEm500 broth. The test tube was placed in a 37°C shaking incubator
overnight.
This broth culture was also used in an inoculation involving the glycerol stock
solution of the transformed E. coli cells. The inoculated flask was placed in the 37°C
shaking incubator overnight.
Brain Hearth Infusion (BHI) broth, Erythromycin Plates:
The medium for the BHIEm1 plates was prepared using 200mL H2O, 7.4g BHI
broth, 3g bacto agar, and 20µL Em10. The transformed B. subtilis (BD366) cells were
spread on these plates, which were then placed in a 30°C incubation chamber for 3 days.
Electroporation Recovery Media:
The recovery medium used for each electroporation product corresponded to the
plates onto which the transformed cells were spread; the recovery medium for the
transformed DH5α cells was LBEm500, while the recovery medium for the transformed
BD366 cells was BHIEm1 broth.
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Recombinant DNA Techniques:
Polymerase Chain Reaction (PCR):
PCR is a standard method for rapidly producing numerous copies of a DNA
segment.20 The first step of PCR is combining the plasmid possessing the DNA sequence
of interest, the master mix, deionized water, and two primers that mimic the beginning
and ending nucleotide sequences that encompass the desired DNA segment. Next, that
mixture is placed in some sort of heating device, such as a thermocycler. The
thermocycler heats the sample to three different temperatures, the first of which being the
temperature required to denature the double-stranded DNA of the plasmid. Once the two
DNA strands have been separated, the sequences are ready to act as templates for the
construction of new strands. Thus begins the annealing stage, during which the
temperature is reduced to allow the primers to adhere to their complementary sequences
on the now single-stranded DNA segments. Finally, the thermocycler raises the
temperature once more to the optimum temperature at which the specific DNA
polymerase functions. During this last step, the DNA polymerase prompts the
deoxynucleotide triphosphates (dNTPs) from the master mix to bind to their
complimentary nucleotides on the DNA segment, starting with the primer. By the end of
this final stage, the single copy of double-stranded DNA coding for the desired DNA
segment has now become two identical copies. This three-stage cycle can be repeated as
many times as necessary until the desired amount of DNA copies have been created.20
The components of the PCR typically include master mix, vent, the target
plasmid, two primers associated with that plasmid, and dH2O. While the master mix
contains Taq, the additional DNA polymerase vent is often utilized because it is capable
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proofreading the new DNA strands and eliminating any potential mutations that occur
during the elongation process. For this experiment, the thermocylcer was set to 94°C for
the denaturing stage, which lasted 30 seconds. The second step ran for 45 seconds at
45°C, which was deemed the appropriate annealing temperature for the AppProR and
UP101 primers. The final stage occurred at 72°C, the optimum temperature for the DNA
polymerases Taq and vent; this step lasted for 60 seconds. This three-step cycle was set to
repeat 30 times.
Restriction Enzyme Digests:
The purpose of a restriction enzyme digest is typically to produce compatible ends
of DNA sequences that can be ligated together, or “sticky ends.” DNA digests typically
involve restriction enzymes that recognize 6-8 consecutive bases.21 This project included
two digests in preparation for a ligation: a pUA321 digest and a pG+host4 digest. The
pUA321 digest consisted of 11µL purified pUA321 PCR product, 32µL dH2O, 5µL
NEBuffer 2.1, 1µL HindIII, and 1µL EcoR1. The pG+host4 digest consisted of 1µL
pG+host4, 42µL dH2O, and equivalent amounts of NEBuffer 2.1, HindIII, and EcoR1 as
outlined in the pUA321 digest. Both digests utilized the same restriction enzymes,
HindIII and EcoR1, in the hopes of producing sticky ends for a future ligation. Each
digest was placed in the 37°C shaking incubator for 1 hour.
Restriction enzyme digests can also be used as a means of preparing a plasmid for
transformation. Studies have shown that transformations of naturally competent B.
subtilis cells produce better results when transformed with linear DNA rather than
circular DNA.8 While this linear DNA preference has not been shown conclusively for
transformation via electroporation, a digest was performed on the ethanol precipitation
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product (EPP) in the hopes of increasing the transformation efficiency of BD366 with the
EPP. The components of this restriction enzyme digest were 2µL EPP, 5µL NEBuffer
2.1, 1µL XbaI, and 42µL dH2O. This digest was also placed in the 37°C shaking
incubator for 1 hour.
Ligation:
Ligations are performed to unify two linear DNA fragments into one circular
piece of DNA. The components of a ligation include a ligation enzyme, the ligation
buffer associated with that enzyme, and the two digests that are being joined. In this
experiment, the ligation mixture was incubated at room temperature overnight.
Purification Techniques:
MicroElute Cycle Pure Kit:
This purification kit is typically used to remove impurities from PCR products.
The protocol in this kit was followed for two purifications during this experiment: the
purification of the pUA321 PCR product and the purification of the pUA321 and
pG+host4 digests prior to their ligation.
MicroElute DNA Cleanup Kit:
This purification kit is typically used to remove impurities from DNA segments
that have been subjected to enzymatic reactions of some sort. The protocol in this kit was
followed to purify the EPP digest prior to the transformation of the BD366 cells via
electroporation.
Electroporation of DH5α and BD366:
Electroporation is the most common physical technique utilized to transform
bacterial cells. Electroporation uses a high-strength electrical pulse to generate temporary
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pores in the membranes of the electrocompetent cells. The plasmid containing the DNA
sequence to be incorporated into the bacterial DNA may enter the cells through those
pores and be recombined into the electrocompetent cells.1 First, the plasmid of interest is
pipetted into a solution of electrocompetent cells. This mixture is pipetted into a chilled
cuvette, which is then placed into a chilled cuvette holder. The cuvette holder is
positioned into the electroporator, which is set according to the needs of the
electrocompetent cells being utilized. After the electrical charge is applied, the time
constant is measured. Finally, recovery medium is added to the cuvette before the
contents of the cuvette are transferred to a Falcon tube for incubation. In this experiment,
the Falcon tube was placed in the 37°C shaking incubator for 2 hours prior to plating the
transformed cells.
Glycerol Stock Solution:
A glycerol stock solution (created from the fluorescent E. coli colony) was
produced so that the transformed E. coli cells containing the pUA625 could be stored in
the -80°C deep freezer and retrieved during future related experiments.
Inoculation:
A flask containing LBEm500 broth was inoculated with 100µL glycerol stock
solution in order to grow cells to be used for the maxi plasmid preparation.
Plasmid Preparation:
Plasmid DNA Maxi Kit:
This plasmid preparation kit produces high copy number plasmid DNA, which is
desirable when executing a bacterial transformation.
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Ethanol Precipitation:
The purpose of an ethanol precipitation is to concentrate DNA through the
centrifugation, washing, and consequent drying of the DNA of interest. The first step in
an ethanol precipitation is to add NaCl and ethanol to the plasmid DNA. The mixture is
then centrifuged to produce a pellet. The pellet is then washed with ethanol, dried by
vacuum centrifugation, and then suspended in a solution.
Horizontal Agarose Gel Electrophoresis:
Agarose gel electrophoresis is a means of separating DNA fragments based on
size. The DNA being evaluated is placed in wells at one end of the gel, and an electric
current is then applied to the gel. The negatively-charged phosphate backbone of the
DNA causes the fragments to move towards the positively charged anode. As the
fragments are migrating through the gel, the network of agarose particles acts as a filter
and catches the DNA fragments in a size-dependent manner; the smaller the DNA
fragment, the more easily it can move through the agarose pores and, thus, the farther it
will travel in the gel.15
This project utilized the Embi Tec “RunOne Electrophoresis Unit” when
performing horizontal agarose gel electrophoresis. The gel itself was composed of TAE,
SeaKem GTG agarose, and SYBR Safe. A 1 kb marker, which produces multiple bands
of varying sizes, was run during every gel that was executed. By simultaneously running
the 1 kb marker with the DNA samples, the ladder created by the marker allowed the
relative sizes of the DNA samples to be estimated. These size estimations served as a
means of verifying various experimental steps, for the expected size of the samples was
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known. The gels, therefore, were extremely helpful in validating the success of the other
experimental methods (figures 3, 4, 8, and 9).
Fluorescence Microscopy:
Fluorescence microscopy is a technique that separates fluorescence excitation and
detection into two distinct light paths. By juxtaposing the axis of illumination and the
axis of detection in a perpendicular manner, the amount of excitation light that is
captured in the image is reduced. This means that the final image is a clearer, better
representation of the degree of fluorescence being emitted by the cells.19
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Results
PCR amplification of Papp:gfp. A fragment suitable for cloning to the app promoter
was produced by PCR, using pUA321 as target DNA, and the primers AppProR and
UP101. The purpose of the PCR was to create numerous linear copies of the DNA
segment that codes for the desired appProR-gfpreporter gene sequence, with flanking DNA sequences
containing restriction endonuclease sequences for the
subsequent cloning experiment. The PCR product was
subjected to horizontal gel electrophoresis, which
revealed a band of 1.2 kb (figure 3), corresponding to
the Papp:gfp gene fragment.
Figure 3: Gel electrophoresis of
pUA321 PCR Product.

	
  
The PCR product was then subjected to the
MicroElute Cycle Pure Kit in preparation for the
subsequent ligation. Horizontal gel electrophoresis
was then utilized to verify the success of this
purification (figure 4); the 1.2 kb band produced
was consistent with the expected size of the
purified PCR product.
Figure 4: Gel electrophoresis of purified
pUA321 PCR Product.
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Ligation of pUA321 and pG+host4. The ligation was executed utilizing T4 ligase and
T4 ligation buffer to unite the purified pUA321 digest with the purified pG+host4 digest.
This fusion of pUA321 with pG+host4 was a vital step in the experiment, for pUA321
would be unable to replicate in both E. coli and B. subtilis if left to its own devices. The
plasmid pG+host4, however, contains a broad host range that permits it to survive in a
variety of gram-negative and gram-positive bacterial species.13 Therefore, the ligation
was carried out to insert the appProR-gfp-reporter sequence from pUA321 into pG+host4
to create a new plasmid, pUA625 (figure 5). This new plasmid was utilized in all
subsequent transformations and steps in the project.

Figure 5: Plasmid Map of pUA625; image generated from the nucleotide sequence
using CLC-Bio DNA Workstation.
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Electroporation of E. coli cells. This electroporation was conducted to incorporate
pUA625 into electrocompetent E. coli cells, or DH5α cells. This experiment used the
Bio-Rad Electroporator, which was set to 25µF, 200 Ohms, and 1.7kV/cm pulse rate, as
is dictated by the DH5α cells. The time constant was recorded as 4.1 ms, which fell into
the range of satisfactory time constants for DH5α cells (3.5 to 4.5 ms).
The time constant of the transformed E. coli cells suggested that the
electroporation was successful, so the cells were spread on an LBEm500 plate. The cells
produced a green fluorescent colony when subjected to epiluminescence with blue light
(figure 6).

Figure 6: A fluorescent E. coli colony on an LBEm500 plate. This image was
captured with a standard Canon camera that was covered with an orange lens.
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Fluorescence microscopy of transformed E. coli cells. Cells from the fluorescent E.
coli colony (figure 6) were subjected to fluorescence microscopy using a Zeiss
Fluorescent AxioImager M1 Upright Motorized Microscope in conjunction with
AxioVision Image Analysis Software, yielding an image of bright green cells (figure 7).

Figure 7: Fluorescent E. coli cells.

Plasmid preparation of transformed E. coli cells. A plasmid preparation was
performed according to the protocol outlined in the Plasmid DNA Maxi Kit. This step
was executed in order to produce a large amount of the
transformed E. coli DNA containing the appProR-gfpreporter sequence, increasing the likelihood that the
upcoming B. subtilis transformation would be successful.
The product of this plasmid preparation was subjected to
horizontal agarose gel electrophoresis (figure 8), which
produced a blurry band of roughly 5 kb that was consistent
with the expected band size of the plasmid. The smallest

Figure 8: Gel electrophoresis of largescale plasmid preparation product.

	
  
bands (less than 500 bp) indicated the presence of residual RNA.
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Ethanol precipitation of the large-scale plasmid preparation product. The purpose of
this precipitation was to concentrate the DNA from the preceding plasmid preparation
product in order to increase the chances for a successful subsequent B. subtilis
transformation. This ethanol precipitation was executed as described by Lever et al
(2015), which started by adding 0.2 volumes 5 M NaCl and 2.5 volumes ethanol (95 %)
to the plasmid preparation product.16 After centrifuging at 20,000 x g for 10 minutes, the
pellet was washed with 70% ethanol and dried by vacuum centrifugation before being
suspended in 10 mM Tris-C (pH 8.0). The resulting ethanol precipitation product (EPP)
was then subjected to horizontal agarose gel electrophoresis (figure 9). Electrophoresis
produced a band of approximately 5 kb, as was expected of the EPP. Additional large
bands arose due to DNA supercoiling, as well small bands (less than 500 bp) indicative of
residual RNA.

Figure 9: Gel electrophoresis of EPP (third well).
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Electroporation of B. subtilis cells. Another electroporation was executed, this time
involving the integration of the purified, digested EPP into electrocompetent B. subtilis
(BD366) cells. For this electroporation, the Bio-Rad Electroporator was set to 25µF, 400
Ohms, and 1.4kV/cm pulse rate. The time constant was recorded as 5.3ms, which fell
under the range of suitable time constants for BD366 cells (4.8 to 5.8 ms).
The time constant of the transformed BD366 cells, suggested that the
electroporation was successful, so the cells were spread on a BHIEm1 plate. The cells
produced multiple green fluorescent colonies when subjected to transillumination with
blue light (figure 10). The fluorescent colonies were labeled pUA630, a designation
which will be used when referring to this strain of transformed B. subtilis cells containing
the appProR-gfp-reporter gene sequence in future Ivey Laboratory experiments.

Figure 10: Fluorescent B. subtilis colonies on a BHIEm1 plate. The colonies
marked through with an “X” are non-fluorescent. This image was captured
with a standard Canon camera that was covered with an orange lens.
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Fluorescence Microscopy of transformed B. subtilis cells. Cells from the fluorescent
pUA630 colonies (figure 10) were subjected to fluorescence microscopy using a Zeiss
Fluorescent AxioImager M1 Upright Motorized Microscope in conjunction with
AxioVision Image Analysis Software microscope, producing an image of vibrant green
cells (figure 11).

Figure 11: Fluorescent B. subtilis cells.
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Discussion
The first achievement of this experiment was the successful cloning of plasmid
pUA625 through the ligation of the purified pUA321 and pG+host4 digests. This step was
essential for the future success of this project, for the appProR-gfp-reporter gene
sequence from pUA321 would not have the host range potential to be incorporated into
C. difficile without pG+host4. The creation of pUA625 was verified when the
transformation of the E. coli cells with the ligation product produced fluorescent colonies,
since E. coli colonies are not naturally fluorescent and must have been expressing the
green fluorescent protein from pUA625. Once the appProR-gfp-reporter construct was
integrated into E. coli, the next phase of the experiment was to incorporate pUA625 into
B. subtilis. This step would be more indicative of the likelihood that a future
transformation of the plasmid into C. difficile would work, since B. subtilis behaves more
similarly than E. coli to C. difficile as a host organism. B. subtilis is not as easily
transformed as E. coli, so the outcome of the second electroporation was less certain.
Thankfully, the transformed B. subtilis strain (pUA630) produced fluorescent colonies,
signifying that this electroporation was also executed effectively.
The incorporation of the appProR-gfp-reporter gene into B. subtilis was a triumph
for the Ivey Laboratory, for it created a model organism in which various aspects of C.
difficile can be further characterized. B. subtilis’s sporulation developmental program, for
example, is one promising target for future research. Since endospore formation is crucial
for C. difficile survival, one could attempt to modify the spore-forming capacities of
pUA630 and then apply those findings to C. difficile. Additionally, pUA630 could be
used in conjunction with the results from previous projects conducted in the Ivey
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Laboratory. CodY, a protein found in gram-positive bacterial species, has been found to
bind and repress the expression of the App promoter in response to C. difficile’s
nutritional environment.2 This repressive function could be instrumental in preventing
CDIs, for stopping the expression of the App system would render the bacterium
incapable of ingesting peptides and perhaps hinder cytotoxin release. By conducting
experiments to further analyze CodY’s suppressive effects on pUA630’s appProR
sequence, the protein’s mechanisms could be better understood and, hopefully, exploited
in C. difficile. By taking advantage of the similarities shared between B. subtilis and C.
difficile, the Ivey Laboratory can determine which methods would be most effective in
preventing C. difficile proliferation by performing tests on a much safer experimental
host, pUA630.
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